Advances in cancer research have revolutionized the way cancer is diagnosed and treated. Any cancer is now known to be an amalgamation of many subtypes, each carrying its specific cancer-causing gene or oncogene. It is also evident that a given oncogene is often present across a wide range of cancer subtypes, albeit at different frequencies. These lines of information have brought cancer genomic medicine (CGM) to the clinic, where genetic information is used to optimize therapeutic intervention. In 2017, the Expert Meeting for Cancer Genomic Medicine Promotion Consortium in the Ministry of Health, Labour and Welfare (MHLW) of Japan submitted a blueprint for the CGM platform in Japan. Accordingly, the MHLW designated a total of 206 hospitals that conduct cancer gene panel testing under the national health insurance system and established the Center for Cancer Genomics and Advanced Therapeutics to store genomic/clinical information of cancer patients. Since June 2019, the CGM officially started in Japan.

癌症研究的进步彻底改变了癌症的诊断和治疗方式。现在已知任何癌症都是许多亚型的融合，每种亚型都携带其特定的致癌基因或癌基因。同样明显的是，给定的癌基因通常存在于多种癌症亚型中，尽管频率不同。这些信息使癌症基因组医学（CGM）进入了临床，在这里，遗传信息被用于优化治疗干预。2017年，日本厚生劳动省癌症基因组医学促进联合会专家会议提交了日本CGM平台的蓝图。因此，MHLW指定了206家根据国家健康保险体系进行癌症基因检测的医院，并建立了癌症基因组学和高级治疗中心来存储癌症患者的基因组/临床信息。自2019年6月起，CGM在日本正式开始。